黄类药物hesperidin和diosmin:肥胖的辅助疗法
Sanjay Kalra1, Atul Dhingra2, Suneet Kumar Verma3
1Department of Endocrinology, Bharti Hospital, Karnal, India; University Center for Research & Development, Chandigarh University, Mohali, India.
JPMA. The Journal of the Pakistan Medical Association
|March 14, 2026
概括
狄奥斯和赫斯佩里丁是用于静脉疾病的黄类药物. 这项研究探讨了它们对肥胖和相关胀 (肥胖) 的潜在益处.
科学领域:
- 药理学和植物化学
- 血管生物学 血管生物学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 黄类是植物衍生的多,具有独特的15碳结构.
- 迪奥斯和赫斯佩里丁是已知的毒和血管保护剂.
- 目前的应用包括静脉缩,慢性静脉不全和.
研究的目的:
- 研究迪奥斯和赫斯佩里丁在肥胖症中的潜在治疗应用.
- 探索它们在管理与肥胖相关的胀,称为肥胖症的有效性.
主要方法:
- 对现有关于黄类药物,迪奥斯和赫斯佩里丁的研究进行文献审查.
- 对代谢和血管健康相关的药理作用的分析.
- 探索背后的性和抗炎作用的机制.
主要成果:
- 狄奥斯和赫斯佩里丁表现出改善血液循环的特性.
- 这些黄素具有抗炎作用,有益于血管健康.
- 有证据表明,在涉及胀和不适的疾病中,可能有缓解症状的可能性.
结论:
- 狄奥斯和赫斯佩里丁在治疗与肥胖相关的胀 (肥胖症) 方面表现有前途.
- 需要进一步的研究来证实它们在肥胖管理中的有效性和最佳使用.
- 黄类药物代表了与肥胖相关的代谢和血管并发症的潜在治疗途径.
相关概念视频
Cancer Prevention
8.6K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
8.6K
Drug Dosing: Obese Patients
325
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
325
Heart Failure VI: Adjunct Therapies
498
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
498
Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
343
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
343
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
262
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
262


